• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RAIN

    Rain Enhancement Technologies Holdco Inc.

    Subscribe to $RAIN
    $RAIN
    Industrial Machinery/Components
    Technology

    Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

    IPO Year:

    Exchange: NASDAQ

    Website: rainthera.com

    Recent Analyst Ratings for Rain Enhancement Technologies Holdco Inc.

    DatePrice TargetRatingAnalyst
    5/30/2023Buy → Neutral
    ROTH MKM
    3/21/2023$11.00Outperform
    SVB Securities
    1/31/2023$21.00Buy
    ROTH Capital
    1/23/2023$18.00Buy
    Mizuho
    9/12/2022$10.00Buy
    H.C. Wainwright
    4/1/2022$15.00Outperform
    Oppenheimer
    9/14/2021$22.00Neutral
    Goldman
    7/20/2021$25.00Overweight
    Piper Sandler
    See more ratings